Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing in vitro fertilization

This study compared two fertility medications (Gynogen HP and Menopur) that are used to help women recruit eggs for IVF treatment. The researchers assessed if these medications are equally potent and safe. The study involved 150 women undergoing their first or second round of IVF between 2019 and 2021. Half of the women received Gynogen HP, while another half received Menopur. The main finding was that both medications worked similarly - women on Gynogen HP recruited an average of 6.3 eggs, while those on Menopur recruited an average of 6.7 eggs. This small difference was not meaningful from a medical perspective. Other important factors, such as pregnancy rates and safety concerns, were also similar between the two medications. Researchers concluded that Gynogen HP works just as well as Menopur for IVF treatment and is equally safe to use. This means doctors can confidently prescribe either medication for women undergoing IVF.